Loading
A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments is a phase 1/2 interventional study registered as NCT06799637 by Evopoint Biosciences Inc., with 350 participants planned, started 2023-12-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: XNW28012.
Shares Evopoint Biosciences, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.